Redhawk Wealth Advisors’s Charles River Laboratories CRL Stock Holding History

Redhawk Wealth Advisors’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-2,986	Closed	-$1.13M	–	221
2021 Q4	$1.13M	Sell	2,986 -990	-25%	-$385K	0.29%	70
2021 Q3	$1.64M	Buy	3,976 +397	+11%	+$165K	0.45%	52
2021 Q2	$1.32M	Buy	3,579 +506	+16%	+$169K	0.3%	75
2021 Q1	$891K	Buy	3,073 +145	+5%	+$40.3K	0.22%	89
2020 Q4	$732K	Buy	2,928 +1,007	+52%	+$240K	0.19%	94
2020 Q3	$435K	Buy	+1,921	New	+$399K	0.13%	135

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Redhawk Wealth Advisors's CRL Position: Q1 2022 in Review

Redhawk Wealth Advisors sold out of Charles River Laboratories (CRL) in Q1 2022, closing a stake of 2,986 shares — an estimated $1.13M sold.

Redhawk Wealth Advisors first reported a position in CRL in Q3 2020 and held it in 6 quarters. The position peaked at $1.64M in Q3 2021. 644 funds tracked by Wall St. Rank hold CRL as of Q1 2022.

Redhawk Wealth Advisors reported no remaining Charles River Laboratories position as of Q1 2022 after selling out during the quarter.
Redhawk Wealth Advisors sold 2,986 Charles River Laboratories shares in Q1 2022, an estimated $1.13M.
Redhawk Wealth Advisors first reported a position in Charles River Laboratories in Q3 2020 and held it in 6 quarters.
Redhawk Wealth Advisors's Charles River Laboratories position peaked at $1.64M in Q3 2021.
644 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2022.

Based on Redhawk Wealth Advisors's 13F filing for Q1 2022, filed 21 Apr 2022.